Tags

Type your tag names separated by a space and hit enter

Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind comparative study.
J Med Assoc Thai 1993; 76(7):388-93JM

Abstract

Sixty-four patients with clinically and mycologically diagnosed tinea corporis and tinea cruris were randomly allocated to receive either 250 mg of oral terbinafine once daily or 500 mg of griseofulvin once daily for 2 wks. Patients in each group were well matched for age, gender, clinical features and type of dermatophytes. Clinical and mycological control tests (KOH wet mount and culture) were performed before treatment, at the end of treatment and 4 wks after stopping treatment. In the majority of cases, the infecting agent was identified as Trichophyton rubrum (53/64). The remainder comprised Trichophyton mentagrophytes (8/64) and Epidermophyton floccosum (3/64). After 2 wks of therapy, there was no significant difference in mycological response in the terbinafine group (90.3%) and griseofulvin group (80.7%). The clinical response in both groups was the same. At 6 wks' follow-up, the mycological cure in terbinafine and griseofulvin group was 87.1 and 54.8 per cent, respectively (P < 0.05). The clinical response of the terbinafine group was also significantly higher than in the griseofulvin group. A higher relapse rate was observed in the griseofulvin group than in the terbinafine group. No serious side effects were reported in either group. The result showed that oral terbinafine was more effective than oral griseofulvin in the treatment of tinea corporis or tinea cruris.

Authors+Show Affiliations

Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

8089640

Citation

Voravutinon, V. "Oral Treatment of Tinea Corporis and Tinea Cruris With Terbinafine and Griseofulvin: a Randomized Double Blind Comparative Study." Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, vol. 76, no. 7, 1993, pp. 388-93.
Voravutinon V. Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind comparative study. J Med Assoc Thai. 1993;76(7):388-93.
Voravutinon, V. (1993). Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind comparative study. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 76(7), pp. 388-93.
Voravutinon V. Oral Treatment of Tinea Corporis and Tinea Cruris With Terbinafine and Griseofulvin: a Randomized Double Blind Comparative Study. J Med Assoc Thai. 1993;76(7):388-93. PubMed PMID: 8089640.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind comparative study. A1 - Voravutinon,V, PY - 1993/7/1/pubmed PY - 1993/7/1/medline PY - 1993/7/1/entrez SP - 388 EP - 93 JF - Journal of the Medical Association of Thailand = Chotmaihet thangphaet JO - J Med Assoc Thai VL - 76 IS - 7 N2 - Sixty-four patients with clinically and mycologically diagnosed tinea corporis and tinea cruris were randomly allocated to receive either 250 mg of oral terbinafine once daily or 500 mg of griseofulvin once daily for 2 wks. Patients in each group were well matched for age, gender, clinical features and type of dermatophytes. Clinical and mycological control tests (KOH wet mount and culture) were performed before treatment, at the end of treatment and 4 wks after stopping treatment. In the majority of cases, the infecting agent was identified as Trichophyton rubrum (53/64). The remainder comprised Trichophyton mentagrophytes (8/64) and Epidermophyton floccosum (3/64). After 2 wks of therapy, there was no significant difference in mycological response in the terbinafine group (90.3%) and griseofulvin group (80.7%). The clinical response in both groups was the same. At 6 wks' follow-up, the mycological cure in terbinafine and griseofulvin group was 87.1 and 54.8 per cent, respectively (P < 0.05). The clinical response of the terbinafine group was also significantly higher than in the griseofulvin group. A higher relapse rate was observed in the griseofulvin group than in the terbinafine group. No serious side effects were reported in either group. The result showed that oral terbinafine was more effective than oral griseofulvin in the treatment of tinea corporis or tinea cruris. SN - 0125-2208 UR - https://www.unboundmedicine.com/medline/citation/8089640/Oral_treatment_of_tinea_corporis_and_tinea_cruris_with_terbinafine_and_griseofulvin:_a_randomized_double_blind_comparative_study_ L2 - https://medlineplus.gov/tineainfections.html DB - PRIME DP - Unbound Medicine ER -